Wei Yang

Wei Yang

Auto-generated profile, based on publicly available information

Wei Yang

Department of Urology, School of Medicine Xinhua Hospital, Shanghai Jiaotong University Shanghai China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Bioactive Materials
Verified
Journal Article
Open access
WYWei Yang
Wei Yang
JCJianwei Cao
Jianwei Cao
HCHui Cheng
Hui Cheng
LCLiang Chen
Liang Chen
MYMeihua Yu
Meihua Yu
XCXingang Cui
Xingang Cui
The approved worldwide use of two messenger RNA (mRNA) vaccines (BNT162b2 and mRNA-1273) in late 2020 has proven the remarkable success of mRNA therapeutics together with lipid nanoformulation technology in protecting people against coronaviruses during COVID-19 pandemic. This unprecedented and exciting dual strategy with nanoformulations and mRNA therapeutics in play is believed to be a promising paradigm in targeted cancer immunotherapy in future. Recent advances in nanoformulation technologies play a prominent role in adapting mRNA platform in cancer treatment. In this review, we introduce the biologic principles and advancements of mRNA technology, and chemistry fundamentals of intriguing mRNA delivery nanoformulations. We discuss the latest promising nano-mRNA therapeutics for enhanced cancer immunotherapy by modulation of targeted specific subtypes of immune cells, such as dendritic cells (DCs) at peripheral lymphoid organs for initiating mRNA cancer vaccine-mediated antigen specific immunotherapy, and DCs, natural killer (NK) cells, cytotoxic T cells, or multiple immunosuppressive immune cells at tumor microenvironment (TME) for reversing immune evasion. We highlight the clinical progress of advanced nano-mRNA therapeutics in targeted cancer therapy and provide our perspectives on future directions of this transformative integrated technology toward clinical implementation.

22 December 2022 in Oncology Reports
Verified
Journal Article
Open access
PDF file
WCWei-Jie Chen
Wei-Jie Chen
WYWei Yang
Wei Yang
MGMin Gong
Min Gong
YHYi He
Yi He
DXDa Xu
Da Xu
XCXingang Cui
Xingang Cui
Clear cell renal cell carcinoma (ccRCC) is a frequent malignant tumor of the kidney which has a dismal prognosis. At present, targeted therapies and immunotherapy have achieved significant results; however, the overall survival rate of patients with ccRCC remains unacceptably poor. It is therefore necessary to find novel therapeutic and diagnostic targets for ccRCC. It has been reported that enolase 2 (ENO2) is an oncogene, although its function in the immune microenvironment and in the growth of ccRCC has yet to be fully elucidated. The present study analyzed the data of patients with ccRCC both from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, and from clinical samples obtained from Third Affiliated Hospital of the Second Military Medical University to investigate the role of ENO2 in the progression of ccRCC and the correlation between ENO2 and certain clinical features. It was found that the expression of ENO2 was elevated both in patients with ccRCC retrieved from the GEO and TCGA databases and in clinical ccRCC samples obtained from Third Affiliated Hospital of the Second Military Medical University. In addition, the prognosis of patients was poorer when ENO2 was highly expressed. Gene Ontology (GO) analysis and Gene Set Enrichment Analysis (GSEA) confirmed that ENO2 participated in the regulation of various pathways in ccRCC. In vitro experiments including Cell Counting Kit‑8 cell proliferation assay, Transwell and Matrigel assays confirmed that ENO2 could promote the proliferation and migration of ccRCC cells. Furthermore, a number of immunosuppressive indicators were identified that positively correlated with ENO2 expression. In conclusion, the present study revealed that ENO2 expression promotes the proliferation, invasion and migration of ccRCC cells, and may serve as a novel predictor to evaluate prognosis and the efficacy of immune checkpoint blockade treatment for patients with ccRCC.

15 November 2022 in Blood
Verified
Journal Article
Open access
WCWenming Chen
Wenming Chen
CFChengcheng Fu
Chengcheng Fu
BFBaijun Fang
Baijun Fang
ALAi-Bin Liang
Ai-Bin Liang
ZXZhongjun Xia
Zhongjun Xia
ZLZonghai Li
Zonghai Li
Background: Zevorcabtagene autoleucel (Zevor-cel, CT053), a fully human autologous anti- B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell

28 April 2025 in Biomaterials
Verified
Journal Article
Closed access
JNJin Nan
Jin Nan
CXChundongqiu Xia
Chundongqiu Xia
JZJingyi Zhang
Jingyi Zhang
YXYujie Xie
Yujie Xie
SSShuyu Shi
Shuyu Shi
JZJun Zhang
Jun Zhang

31 January 2025 in Science Advances
Verified
Journal Article
Open access
WYWei Yang
Wei Yang
SDSichen Di
Sichen Di
ZYZihuan Yang
Zihuan Yang
JCJianwei Cao
Jianwei Cao
QFQingqiao Fu
Qingqiao Fu
XCXingang Cui
Xingang Cui
Cancer immunotherapies rely on CD8 + cytolytic T lymphocytes (CTLs) in recognition and eradication of tumor cells via antigens presented on major histocompatibility complex class I (MHC-I) molecules. However, we observe MHC-I deficiency in human and murine urologic tumors, posing daunting challenges for successful immunotherapy. We herein report an unprecedented nanosonosensitizer of one-dimensional bamboo-like multisegmented manganese dioxide@manganese–bismuth vanadate (BMMBV) to boost multiple branches of immune responses targeting MHC-I–deficient tumors. BMMBV markedly augments sonodynamic activity contributed by manganese heteroatoms in the lattice of bismuth vanadate with narrowing bandgaps. Under sonoirradiation, BMMBV enhances tumor antigen spreading and emission of adjuvant signals, which potentiate dendritic cell maturation, thereby eliciting high aptitude of CTLs. This therapy substantially up-regulates MHC expression on tumor cells, which are reversely sensitive to CTLs. Alongside, extensive innate immune cells complement the cytolytic activity of CTLs for eliminating mouse urologic tumors. This study offers a reinforced strategy against antigen-loss immune-evasive tumor.

11 September 2026 in Angewandte Chemie
Verified
Journal Article
Closed access
HRHongze Ren
Hongze Ren
QWQingying Wu
Qingying Wu
WYWei Yang
Wei Yang
ZTZhengqi Tang
Zhengqi Tang
LXLili Xia
Lili Xia
Yu ChenYu Chen
Yu Chen